Coronaviruses
Seven members of the coronavirus family are already known to infect people, often with deadly consequences - and novel coronaviruses are continuing to be discovered. 成人VR视频鈥檚 coronavirus R&D investments focus on two of its priority pathogens鈥擟OVID-19 and MERS鈥攁s well as broadly protective coronavirus vaccines and the establishment of a coronavirus vaccine library.
COVID-19
COVID-19 is caused by SARS-CoV-2 and is part of the Coronavirus family. When COVID-19 struck in January 2020, 成人VR视频 was primed, launching some of the earliest COVID-19 vaccine programmes. 成人VR视频 went onto create one of the largest and most diverse COVID-19 vaccine portfolios, and co-founded and co-led COVAX.
MERS
Middle East Respiratory Syndrome (MERS) is a respiratory illness caused by the MERS coronavirus (MERS-CoV).
MERS-CoV was first identified in 2012 and most cases have been reported from the Arabian Peninsula. In 2015, however, the Republic of Korea suffered the largest MERS outbreak outside of the Middle East.
Broadly protective coronavirus vaccines
The 21st century has seen three coronavirus epidemics or pandemics already. That is why 成人VR视频 is a leading funder of research into broadly protective coronavirus vaccines, which could protect against known and future coronaviruses with epidemic and pandemic potential.
A Coronavirus vaccine library
To combat the broader risk posed by potential spillover of novel coronaviruses from animals to humans, 成人VR视频 has initiated efforts to establish a 鈥淐oronavirus vaccine library鈥濃攁 repository of data and knowledge about vaccines targeting this viral family, intended to accelerate vaccine development against future Coronavirus threats. This approach includes work to prioritise potential Coronavirus threats; design immunogens against these prioritised pathogens, which could be used as vaccine targets; support preclinical testing of potential vaccine targets on various vaccine platforms; and support clinical testing of the most promising candidates to ascertain Phase 1 safety and immunogenicity.
